Overview

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Status:
Recruiting
Trial end date:
2030-11-01
Target enrollment:
Participant gender:
Summary
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy drugs, such as fluorouracil, irinotecan, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before and after surgery (perioperatively) may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery (adjuvantly).
Phase:
Phase 3
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborator:
National Cancer Institute (NCI)
Treatments:
Calcium
Calcium, Dietary
Fluorouracil
Irinotecan
Leucovorin
Levoleucovorin
Oxaliplatin